Biospace

• NanoViricides announced on September 8, 2026, that it has registered a Phase II clinical trial for NV-387 oral gummies to treat the Bundibugyo ebolavirus outbreak in the Democratic Republic of Congo. • The company reports that NV-387 previously performed better than the drug Remdesivir in a lethal animal model of a viral disease. • This trial addresses a critical gap in healthcare because there is currently no approved vaccine or treatment for the specific strain of ebolavirus causing the expanding outbreak.

• Belgium and the Netherlands have developed some of Europe's most robust life sciences ecosystems through a combination of top research institutions and biotech talent. • Investment in these regions is currently fragmented and early-stage funding remains scarce for new ventures. • National biotech initiatives and European Union support serve as the primary catalysts for scaling these scientific strengths into larger commercial markets.

• The FDA has approved Pasatru™ (garetosmab-grts) as the first and only treatment to reduce new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with Fibrodysplasia Ossificans Progressiva (FOP). • The approval follows the OPTIMA Phase 3 clinical trial, a multinational study designed to evaluate the drug's efficacy, safety, tolerability, and pharmacokinetics in patients with active FOP. • This development is significant as it provides a targeted therapeutic option for a rare disease, supported by previous Fast Track and Orphan Drug designations from the FDA, EMA, and Japan's Ministry of Health.

• NanoViricides has received regulatory approval to launch a Phase II clinical trial for NV-387 oral gummies to treat Ebola in the Democratic Republic of Congo. • The trial aims to combat the current outbreak, which is described as the largest and most expanding in the region's history. • Led by Professor Katoto and supported by experts like Fogarty Fellow Patrick, the study leverages specialized implementation research networks to scale novel treatments.

• NanoViricides has received regulatory approval to launch a Phase II clinical trial for NV-387 oral gummies, designed as a treatment for the Ebola virus. • The trial will take place in the Democratic Republic of Congo to combat the largest and most rapidly expanding Ebola outbreak on record. • The urgency for the treatment is heightened by the virus spreading into displacement camps housing over 4.4 million people, where poor sanitation and medical resources increase risk.

• The FDA has approved a new engineered viral immunotherapy designed specifically for patients suffering from treatment-resistant advanced melanoma. • This approval provides a critical new therapeutic option for cancer patients who have failed to respond to existing standard-of-care treatments. • The authorization is granted under conditions where continued market availability may be contingent upon the verification of clinical benefits.

• Moderna has launched a first-in-human Phase 1 clinical trial (NCT07737717) for mRNA-1469, an investigational vaccine targeting the Bundibugyo ebolavirus (BDBV). • The study is being conducted across three sites in Canada and aims to enroll approximately 80 healthy adult participants to evaluate safety, tolerability, and immunogenicity. • This development is critical because while vaccines exist for Zaire ebolavirus, there are currently no approved vaccines to protect against BDBV, which has caused outbreaks in the Democratic Republic of the Congo.

• A Congressional advisory panel has warned that the U.S. is losing its lead in rare disease drug development, labeling the trend a matter of national security. • To combat this, the panel recommends implementing supportive policies, including a finalized FDA platform designation and the adoption of novel trial designs for small patient populations. • The FDA is already taking action via a new pilot program to shorten the timeline from drug identification to first-in-human studies and improve submission quality.

• The FDA experienced a slight slowdown in regulatory productivity during the first half of 2024 due to significant leadership instability and ongoing workforce attrition. • Under acting commissioner Kyle Diamantas, the agency has shifted toward a more open stance, particularly regarding rare disease therapies and accelerated approval applications. • Key beneficiaries of this shift include REGENXBIO, which was told its clinical data for RGX-121 was sufficient, as well as Replimune and uniQure.

• HCA Healthcare has announced a new study published in the New England Journal of Medicine (NEJM) highlighting advancements in CRISPR-based therapies for children. • The research builds upon pioneering work at TriStar Centennial Medical Center and the Sarah Cannon Transplant and Cellular Therapy Network, which performs over 1,600 cellular therapies and transplants annually. • Dr. Frangoul, a key investigator, previously contributed to the first U.S. clinical trial for gene-editing in sickle cell disease, leading to the first FDA-approved CRISPR therapy.

• The U.S. Department of Health and Human Services (HHS) and the FDA have launched an "unprecedented" initiative to restore American leadership in clinical trials and counter competition from China. • A key component of the plan is an expedited investigational new drug pilot program designed to reduce early trial timelines by as much as 12 months. • Health Secretary Robert F. Califf stated the effort aims to reverse the trend of clinical research moving overseas by making the U.S. the premier location for medicine development.

• Former leaders from the FDA, CDC, and NIH convened at the BIO International Convention to discuss the dismantling of the Department of Health and Human Services under the Trump administration. • The panel focused on the collapse of existing US public health structures and the urgent need to rebuild a more effective system. • Experts warned that immediate action is required as infectious disease outbreaks, including Ebola and hantavirus, are becoming increasingly common.

• The drug discovery technology market is projected to grow significantly, with its total size expected to surpass USD 80.27 billion by 2035. • Growth is primarily driven by the integration of genomic data and testing, which allow researchers to identify novel drug targets and analyze DNA variations. • These advancements matter because they reduce compound testing failures and enable precision medicine, ensuring preclinical validation before expensive clinical trials begin.